Transition probability | | | | | | |
tpStoS_folfox_1 | 0.555 | transition probability remain in stable state (folfox)_month1-3 | Beta | 0.555 | 0.111 | Bokemeyer et al, 2011 |
tpStoS_folfox_2 | 0.493 | transition probability remain in stable state (folfox)_month4-6 | Beta | 0.493 | 0.099 | Bokemeyer et al, 2011 |
tpStoS_folfox_3 | 0.410 | transition probability remain in stable state (folfox)_month7-9 | Beta | 0.410 | 0.082 | Bokemeyer et al, 2011 |
tpStoS_folfox_4 | 0.316 | transition probability remain in stable state (folfox)_month10-12 | Beta | 0.316 | 0.063 | Bokemeyer et al, 2011 |
tpStoD_year_1 | 0.005 | transition probability from stable disease to death_year1 | Beta | 0.005 | 0.001 | WHO lifetable |
tpStoD_year_2 | 0.009 | transition probability from stable disease to death_year2 | Beta | 0.009 | 0.002 | WHO lifetable |
tpStoD_year_3 | 0.015 | transition probability from stable disease to death_year3 | Beta | 0.015 | 0.003 | WHO lifetable |
tpStoD_year_4 | 0.023 | transition probability from stable disease to death_year4 | Beta | 0.023 | 0.005 | WHO lifetable |
tpStoD_year_5 | 0.038 | transition probability from stable disease to death_year5 | Beta | 0.038 | 0.008 | WHO lifetable |
tpPtoD_folfox_1 | 0.023 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month1-6 | Beta | 0.023 | 0.005 | Bokemeyer et al, 2011 |
tpPtoD_folfox_2 | 0.031 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month7-12 | Beta | 0.031 | 0.006 | Bokemeyer et al, 2011 |
tpPtoD_folfox_3 | 0.056 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month13-18 | Beta | 0.056 | 0.011 | Bokemeyer et al, 2011 |
tpPtoD_folfox_4 | 0.075 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month19-24 | Beta | 0.075 | 0.015 | Bokemeyer et al, 2011 |
tpPtoD_folfox_5 | 0.040 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month25-30 | Beta | 0.040 | 0.008 | Bokemeyer et al, 2011 |
tpPtoD_folfox_6 | 0.037 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month31-36 | Beta | 0.037 | 0.007 | Bokemeyer et al, 2011 |
tpStoS_folfiri_1 | 0.569 | transition probability remain in stable state (folfiri)_month1-3 | Beta | 0.569 | 0.114 | Bokemeyer et al.,2011 (adjusted with RR_folfiri) |
tpStoS_folfiri_2 | 0.486 | transition probability remain in stable state (folfiri)_month4-6 | Beta | 0.486 | 0.097 | Bokemeyer et al.,2011 (adjusted with RR_folfiri) |
tpStoS_folfiri_3 | 0.406 | transition probability remain in stable state (folfiri)_month7-9 | Beta | 0.406 | 0.081 | Bokemeyer et al.,2011 (adjusted with RR_folfiri) |
tpStoS_folfiri_4 | 0.335 | transition probability remain in stable state (folfiri)_month10-12 | Beta | 0.335 | 0.067 | Bokemeyer et al.,2011 (adjusted with RR_folfiri) |
tpPtoD_folfiri_1 | 0.025 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month1-6 | Beta | 0.025 | 0.005 | Bokemeyer et al.,2011 (adjusted with RR_folfiri) |
tpPtoD_folfiri_2 | 0.034 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month7-12 | Beta | 0.034 | 0.007 | Bokemeyer et al.,2011 (adjusted with RR_folfiri) |
tpPtoD_folfiri_3 | 0.062 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month13-18 | Beta | 0.062 | 0.012 | Bokemeyer et al.,2011 (adjusted with RR_folfiri) |
tpPtoD_folfiri_4 | 0.083 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month19-24 | Beta | 0.083 | 0.017 | Bokemeyer et al.,2011 (adjusted with RR_folfiri) |
tpPtoD_folfiri_5 | 0.045 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month25-30 | Beta | 0.045 | 0.009 | Bokemeyer et al.,2011 (adjusted with RR_folfiri) |
tpPtoD_folfiri_6 | 0.040 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month31-36 | Beta | 0.040 | 0.008 | Bokemeyer et al.,2011 (adjusted with RR_folfiri) |
tpStoS_cetfolfox_1 | 0.761 | transition probability remain in stable state (cetuxfolfox)_month1-3 | Beta | 0.761 | 0.152 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpStoS_cetfolfox_2 | 0.678 | transition probability remain in stable state (cetuxfolfox)_month4-6 | Beta | 0.678 | 0.136 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpStoS_cetfolfox_3 | 0.589 | transition probability remain in stable state (cetuxfolfox)_month7-9 | Beta | 0.589 | 0.118 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpStoS_cetfolfox_4 | 0.501 | transition probability remain in stable state (cetuxfolfox)_month10-12 | Beta | 0.501 | 0.100 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpPtoD_cetfolfox_1 | 0.022 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month1-6 | Beta | 0.022 | 0.004 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpPtoD_cetfolfox_2 | 0.029 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month7-12 | Beta | 0.029 | 0.006 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpPtoD_cetfolfox_3 | 0.053 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month13-18 | Beta | 0.053 | 0.011 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpPtoD_cetfolfox_4 | 0.071 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month19-24 | Beta | 0.071 | 0.014 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpPtoD_cetfolfox_5 | 0.038 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month25-30 | Beta | 0.038 | 0.008 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpPtoD_cetfolfox_6 | 0.035 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month31-36 | Beta | 0.035 | 0.007 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpStoS_cetfolfiri_1 | 0.705 | transition probability remain in stable state (cetuxfolfiri)_month1-3 | Beta | 0.705 | 0.141 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfiri) |
tpStoS_cetfolfiri_2 | 0.619 | transition probability remain in stable state (cetuxfolfiri)_month4-6 | Beta | 0.619 | 0.124 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfiri) |
tpStoS_cetfolfiri_3 | 0.531 | transition probability remain in stable state (cetuxfolfiri)_month7-9 | Beta | 0.531 | 0.106 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfiri) |
tpStoS_cetfolfiri_4 | 0.446 | transition probability remain in stable state (cetuxfolfiri)_month10-12 | Beta | 0.446 | 0.089 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfiri) |
tpPtoD_cetfolfiri_1 | 0.024 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month1-6 | Beta | 0.024 | 0.005 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpPtoD_cetfolfiri_2 | 0.032 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month7-12 | Beta | 0.032 | 0.006 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpPtoD_cetfolfiri_3 | 0.057 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month13-18 | Beta | 0.057 | 0.011 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpPtoD_cetfolfiri_4 | 0.077 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month19-24 | Beta | 0.077 | 0.015 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpPtoD_cetfolfiri_5 | 0.041 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month25-30 | Beta | 0.041 | 0.008 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
tpPtoD_cetfolfiri_6 | 0.037 | transition probability from progressive to death (2nd line - cetux + folfiri as proxy)_month31-36 | Beta | 0.037 | 0.007 | Bokemeyer et al.,2011 (adjusted with RR_cetfolfox) |
Costs | | | | | | |
Direct medical cost | | | | | | |
CostDM_S_cetuxfolfiri | 12,585,566 | direct medical cost related stable state (cetuximab + folfiri) | Gamma | 12,585,566 | 1,018,760 | Hospital billing |
CostDM_S_cetuxfolfox | 10,987,794 | direct medical cost related stable state (cetuximab + folfox) | Gamma | 10,987,794 | 914,930 | Hospital billing |
CostDM_S_folfiri | 12,585,566 | direct medical cost related stable state (folfiri) | Gamma | 12,585,566 | 1,018,760 | Hospital billing |
CostDM_S_folfox | 10,987,794 | direct medical cost related stable state (folfox) | Gamma | 10,987,794 | 914,930 | Hospital billing |
CostDM_P_progressive | 7,609,000 | direct medical cost related progressive state (2nd line - cetux + folfiri as proxy) | Gamma | 7,609,000 | 1,575,518 | Hospital billing |
Direct non-medical cost | | | | | | |
CostDnM_S_cetuxfolfiri | 5,007,500 | direct non-medical cost related stable state (cetuximab + folfiri) | Gamma | 5,007,500 | 346,142 | Interview |
CostDnM_S_cetuxfolfox | 5,007,500 | direct non-medical cost related stable state (cetuximab + folfox) | Gamma | 5,007,500 | 346,142 | Interview |
CostDnM_S_folfiri | 5,007,500 | direct non-medical cost related stable state (folfiri) | Gamma | 5,007,500 | 346,142 | Interview |
CostDnM_S_folfox | 5,007,500 | direct non-medical cost related stable state (folfox) | Gamma | 5,007,500 | 346,142 | Interview |
CostDnM_P_progressive | 6,400,000 | direct non-medical cost related progressive state (2nd line - cetux + folfiri as proxy) | Gamma | 6,400,000 | 756,670 | Interview |
Indirect cost | | | | | | |
CostIn_S_cetuxfolfiri | 5,356,364 | indirect medical cost related stable state (cetuximab + folfiri vs folfiri) | Gamma | 5,356,364 | 786,831 | Interview |
CostIn_S_cetuxfolfox | 5,356,364 | indirect medical cost related stable state (cetuximab + folfox vs folfox) | Gamma | 5,356,364 | 786,831 | Interview |
CostIn_S_folfiri | 5,356,364 | indirect medical cost related stable state (folfiri) | Gamma | 5,356,364 | 786,831 | Interview |
CostIn_S_folfox | 5,356,364 | indirect medical cost related stable state (folfox) | Gamma | 5,356,364 | 786,831 | Interview |
CostIn_P_progressive | 5,493,333 | indirect medical cost related progressive state (2nd line - cetux + folfiri as proxy) | Gamma | 5,493,333 | 786,831 | Interview |
Cost of drug | | | | | | |
Cetuximab | 37,172,895 | drug cost for cetuximab | Gamma | 37,172,895 | 1,760,895 | Hospital billing |
Folfiri | 8,353,539 | drug cost for folfiri | Gamma | 8,353,539 | 763,444 | Hospital billing |
Folfox | 10,310,812 | drug cost for folfox | Gamma | 10,310,812 | 1,083,800 | Hospital billing |
Discounting | | | | | | |
D_cost | 0.030 | discount rate for costs | | | | HTA Indonesia guideline |
D_outcome | 0.030 | discount rate for benefit | | | | HTA Indonesia guideline |
Utility | | | | | | |
U_stable | 0.798 | utility related stable state | Beta | 0.798 | 0.031 | Interview |
U_progressive | 0.443 | utility related progressive state | Beta | 0.443 | 0.154 | Interview |
Relative Risk | | | | | | |
RR_cetuxfolfox_death | 0.948 | Relative risk cetux + folfox for death (folfox as reference) | Lognormal | 0.948 | 0.080 | Network MA |
RR_cetuxfolfiri_death | 1.026 | Relative risk cetux + folfiri for death (folfox as reference) | Lognormal | 1.026 | 0.108 | Network MA |
RR_folfiri_death | 1.109 | Relative risk folfiri for death (folfox as reference) | Lognormal | 1.109 | 0.113 | Network MA |
RR_cetuxfolfox_resrate | 1.644 | Relative risk cetux + folfox for response rate (folfox as reference) | Lognormal | 1.644 | 0.211 | Network MA |
RR_cetuxfolfiri_resrate | 1.400 | Relative risk cetux + folfiri for response rate (folfox as reference) | Lognormal | 1.400 | 0.179 | Network MA |
RR_folfiri_resrate | 0.965 | Relative risk folfiri for response rate (folfox as reference) | Lognormal | 0.965 | 0.114 | Network MA |